Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease-Reference-Cited by-同舟云学术

Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease

Published:2018-05-30 Issue:2 Volume:48 Page:114-126
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Ma C.¹²^ORCID,Dutton S. J.³,Cipriano L. E.⁴⁵,Singh S.⁶⁷^ORCID,Parker C. E.²,Nguyen T. M.²,Guizzetti L.²,Gregor J. C.⁸,Chande N.⁸,Hindryckx P.⁹,Feagan B. G.²⁴⁸^ORCID,Jairath V.²⁴⁸^ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology; Cumming School of Medicine; University of Calgary; Calgary AB Canada

2. Robarts Clinical Trials; Western University; London ON Canada

3. Oxford Clinical Trials Research Unit and Centre for Statistics in Medicine; Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences; University of Oxford; Oxford UK

4. Department of Epidemiology and Biostatistics; Western University; London ON Canada

5. Ivey Business School; Western University; London ON Canada

6. Division of Biomedical Informatics; University of California San Diego; La Jolla CA USA

7. Division of Gastroenterology; University of California San Diego; La Jolla CA USA

8. Division of Gastroenterology; Department of Medicine; Western University; London ON Canada

9. Department of Gastroenterology; University Hospital of Ghent; Ghent Belgium

Funder

Canadian Association of Gastroenterology

Canadian Institutes of Health Research

American College of Gastroenterology Junior Faculty Development Award

Crohn's and Colitis Foundation Career Development Award

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14821/fullpdf

Reference84 articles.

1. Treat to target: a proposed new paradigm for the management of Crohn's disease;Bouguen;Clin Gastroenterol Hepatol,2015

2. Novel therapies in inflammatory bowel disease: an evaluation of the evidence;Narula;Am J Gastroenterol Suppl,2016

3. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management;Dignass;J Crohns Colitis,2010

4. Development of the Lemann index to assess digestive tract damage in patients with Crohn's disease;Pariente;Gastroenterology,2015

5. Aminosalicylates for induction of remission or response in Crohn's disease;Lim;Cochrane Database Syst Rev,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural Products as Dietary Agents for the Prevention and Mitigation of Oxidative Damage and Inflammation in the Intestinal Barrier;Antioxidants;2024-01-01

2. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy;Gastroenterología y Hepatología;2023-03

3. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy;Gastroenterología y Hepatología (English Edition);2023-03

4. Medical Therapy for Crohn’s Disease;The ASCRS Textbook of Colon and Rectal Surgery;2021-11-21

5. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn’s Disease Treated with Anti-metabolite Therapy;Digestive Diseases and Sciences;2021-11-19